Compare Merck & Co., Inc. (MRK) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs PubMatic Inc — how do they compare? Merck & Co., Inc. trades at $141.98 (market cap $351.28B), while PubMatic Inc trades at $18.56 (market cap $850.88M). The key difference: Merck & Co., Inc. is far larger — about 412.8× PubMatic Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and PubMatic Inc for 40 Days on average.
| MRK | PUBM | |
|---|---|---|
Market Cap | $351.28B | $850.88M |
Volume | 7,969,665 | 997,698 |
Sector | Health | Technology |
52-Week High | $156.43 | $19.18 |
52-Week Low | $82.49 | $6.28 |
Typical Hold Time | 98 Days | 40 Days |
Enterprise Value | $398.04B | $754.01M |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
PubMatic trades at $18.57, up 1.2% with a bullish technical signal. The stock shows strong analyst support with 11 buy ratings and a $19.89 consensus target. Recent Q2 2026 earnings beat expectations with $0.12 EPS versus $0.03 estimate, while revenue grew 10.5% year-over-year. The company maintains robust operating cash flow of $81M in 2025 and has strengthened its leadership with new executive appointments.
Despite negative net margins, PubMatic demonstrates operational strength through consistent cash generation and revenue growth. The primary investment opportunity lies in AI-driven ad tech expansion and market share gains, while risks include competitive pressures and profitability challenges. The stock appears fairly valued with potential upside to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
